Mal Irvine

505 total citations
11 papers, 340 citations indexed

About

Mal Irvine is a scholar working on Oncology, Molecular Biology and Ophthalmology. According to data from OpenAlex, Mal Irvine has authored 11 papers receiving a total of 340 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 6 papers in Molecular Biology and 2 papers in Ophthalmology. Recurrent topics in Mal Irvine's work include Cancer-related Molecular Pathways (3 papers), Cancer Immunotherapy and Biomarkers (3 papers) and Melanoma and MAPK Pathways (3 papers). Mal Irvine is often cited by papers focused on Cancer-related Molecular Pathways (3 papers), Cancer Immunotherapy and Biomarkers (3 papers) and Melanoma and MAPK Pathways (3 papers). Mal Irvine collaborates with scholars based in Australia, Germany and United Kingdom. Mal Irvine's co-authors include Helen Rizos, Richard Kefford, Ashleigh Stewart, Bernadette Pedersen, Suzanah C. Boyd, Richard A. Scolyer, Matteo S. Carlino, Georgina V. Long, Carina Fung and Therese M. Becker and has published in prestigious journals such as Cell, Nature Communications and Clinical Cancer Research.

In The Last Decade

Mal Irvine

11 papers receiving 337 citations

Peers

Countries citing papers authored by Mal Irvine

Since Specialization

Citations

This map shows the geographic impact of Mal Irvine's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mal Irvine with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mal Irvine more than expected).

Fields of papers citing papers by Mal Irvine

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mal Irvine. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mal Irvine. The network helps show where Mal Irvine may publish in the future.

Co-authorship network of co-authors of Mal Irvine

This figure shows the co-authorship network connecting the top 25 collaborators of Mal Irvine. A scholar is included among the top collaborators of Mal Irvine based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mal Irvine. Mal Irvine is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

#	Work	Indexed citations
1	The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma 2023 ·Nature Communications ·Su Yin Lim, Elena Shklovskaya, Jenny Lee, Bernadette Pedersen, Ashleigh Stewart, (unknown), Mal Irvine, Brindha Shivalingam, Robyn P.M. Saw, Alexander M. Menzies, Matteo S. Carlino, Richard A. Scolyer, Georgina V. Long, Helen Rizos	67
2	Protein kinase inhibitor responses in uveal melanoma reflects a diminished dependency on PKC-MAPK signaling 2022 ·Cancer Gene Therapy ·John Park, Ashleigh Stewart, Mal Irvine, Bernadette Pedersen, (unknown), Matteo S. Carlino, Russell J. Diefenbach, Helen Rizos	12
3	Durable Responses to Anti-PD1 and Anti-CTLA4 in a Preclinical Model of Melanoma Displaying Key Immunotherapy Response Biomarkers 2022 ·Cancers ·Elena Shklovskaya, Bernadette Pedersen, Ashleigh Stewart, (unknown), (unknown), Mal Irvine, Richard A. Scolyer, Georgina V. Long, Helen Rizos	2
4	Label-Free Fluorescent Poly(amidoamine) Dendrimer for Traceable and Controlled Drug Delivery 2019 ·Biomacromolecules ·Guoying Wang, Libing Fu, Adam K. Walker, Xianfeng Chen, David B. Lovejoy, (unknown), Albert Lee, Roger S. Chung, Helen Rizos, Mal Irvine, Meng Zheng, Xiuhua Liu, Yiqing Lu, Bingyang Shi	23
5	Uveal melanoma cell lines depend on multiple signaling pathways for survival 2019 ·Annals of Oncology ·(unknown), Ashleigh Stewart, Mal Irvine, Bernadette Pedersen, Richard Kefford, Russell J. Diefenbach, Matteo S. Carlino, Helen Rizos	1
6	Oncogenic PI3K/AKT promotes the step-wise evolution of combination BRAF/MEK inhibitor resistance in melanoma 2018 ·Oncogenesis ·Mal Irvine, Ashleigh Stewart, Bernadette Pedersen, Suzanah C. Boyd, Richard Kefford, Helen Rizos	71
7	Preexisting MEK1P124 Mutations Diminish Response to BRAF Inhibitors in Metastatic Melanoma Patients 2014 ·Clinical Cancer Research ·Matteo S. Carlino, Carina Fung, Hamideh Shahheydari, Jason R. Todd, Suzanah C. Boyd, Mal Irvine, Adnan Nagrial, Richard A. Scolyer, Richard Kefford, Georgina V. Long, Helen Rizos	53
8	Predicting functional significance of cancer-associated p16INK4a mutations in CDKN2A 2010 ·Human Mutation ·Heather McKenzie, Carina Fung, Therese M. Becker, Mal Irvine, Graham J. Mann, Richard Kefford, Helen Rizos	27
9	Amino terminal hydrophobic import signals target the p14ARF tumor suppressor to the mitochondria 2010 ·Cell Cycle ·Mal Irvine, (unknown), (unknown), (unknown), Stuart Gallagher, Carina Fung, Therese M. Becker, Richard Kefford, Helen Rizos	13
10	IGFBP7 Is Not Required for B-RAF-Induced Melanocyte Senescence 2010 ·Cell ·Lyndee L. Scurr, Gulietta M. Pupo, Therese M. Becker, (unknown), David Schrama, Sebastian Haferkamp, Mal Irvine, Richard A. Scolyer, Graham J. Mann, Jürgen C. Becker, Richard Kefford, Helen Rizos	50
11	p14ARF Regulates E2F-1 Ubiquitination and Degradation via a p53-Dependent Mechanism 2007 ·Cell Cycle ·Helen Rizos, Lyndee L. Scurr, Mal Irvine, (unknown), Richard Kefford	21

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact